Swedish Firms Pledpharma And RTT Merge To Target Orphan Drug Space
Two Late-Stage Assets For Rare Diseases
Following the failure of PledOx, Pledpharma is joining forces with Rare Thyroid Therapeutics to target orphan treatments, initially focusing on the latter's investigational therapy for MCT8 deficiency.
You may also be interested in...
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.